Insider Trading History of Amello Jason

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Amello Jason since 2010. The trader's CIK number is 1451805. At the time of the last reporting, Amello Jason was the CorpContrllr,ChiefAccntOfficer of Akebia Therapeutics, Inc.. (stock ticker symbol AKBA). Also see all insider trading activities at Akebia Therapeutics, Inc..

Note that in the past Amello Jason also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Genzyme Corp (GENZ) by Amello Jason

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2011 GENZ 0 $0 0 $0 5,005 $0
2010 GENZ 0 $0 7,173 $491,107 8,215 $307,033

Yearly summary of insider trading at Akebia Therapeutics, Inc. (AKBA) by Amello Jason

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2020 AKBA 0 $0 6,976 $60,691 0 $0
2014 AKBA 5,000 $81,220 0 $0 0 $0


Insider trading activities at 2 companies by Amello Jason:

1. Genzyme Corp (GENZ)

2. Akebia Therapeutics, Inc. (AKBA)

Table 1. Insider trading of Genzyme Corp (GENZ) by Amello Jason

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2011-04-04 GENZ Option Ex 5,005 .00 0
2010-08-31 GENZ Sale 6,640 70.30 466,792
2010-08-31 GENZ Option Ex 6,640 46.24 307,033
2010-05-24 GENZ Option Ex 1,575 .00 0
2010-05-25 GENZ Sale 533 45.62 24,315

Table 2. Insider trading of Akebia Therapeutics, Inc. (AKBA) by Amello Jason

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2020-02-28 AKBA Sale 6,976 8.70 60,691
2014-11-26 AKBA Buy 1,000 13.22 13,220
2014-03-25 AKBA Buy 4,000 17.00 68,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Amello Jason (CorpContrllr,ChiefAccntOfficer of Akebia Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.